« Back
Home /
Laduviglusib trihydrochloride

Laduviglusib trihydrochloride

Item no.	DCC-DC23985-250mg
Manufacturer	DCChemicals
CASRN	1782235-14-6
Amount	250 mg
Quantity options	100 mg 10 mg 1 g 250 mg 50 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Applications	IC, other
Specific against	other
Purity	>98%
Smiles	ClC1C([H])=C(C([H])=C([H])C=1C1C(=C([H])N=C(N=1)N([H])C([H])([H])C([H])([H])N([H])C1C([H])=C([H])C(C#N)=C([H])N=1)C1=NC([H])=C(C([H])([H])[H])N1[H])Cl.Cl[H].Cl[H].Cl[H]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Available
Manufacturer - Applications	Laduviglusib (CHIR-99021) trihydrochloride is a well-characterized small molecule inhibitor that specifically targets glycogen synthase kinase-3 alpha and beta (GSK-3α/β). It exhibits potent inhibitory activity with IC50 values of 10 nM for GSK-3α and 6.7 nM for GSK-3β. Importantly, it demonstrates high selectivity, being over 500-fold more selective for GSK-3 compared to other kinases such as CDC2 and ERK2, as well as a broad range of other protein kinases.
Molecular Weight	574, 7207

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 250 mg

available

Delivery expected until 2/26/2026

Compare

Add to wishlist

Get an offer

Request delivery time